Working… Menu
Trial record 1 of 1 for:    NCT03112603
Previous Study | Return to List | Next Study

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03112603
Recruitment Status : Active, not recruiting
First Posted : April 13, 2017
Last Update Posted : May 7, 2021
Information provided by (Responsible Party):
Incyte Corporation